SRPT Sarepta Therapeutics, Inc. Insider Trading

Director Wigzell sells 10,500 SRPT shares at $124.84 (−31.5% of holdings); prior 4 SRPT sales all showed negative 90d returns.

Wigzell Hans Lennart Rudolf, a director of Sarepta Therapeutics, sold 10,500 shares (−31.5% of prior holdings) on 2024-12-12 at $124.84 per share for $1,310,820.00. His prior trading history at this ticker is notably consistent: all 4 prior sales at SRPT occurred on 2024-03-08 and 2023-08-04, and each showed negative 90-day returns (−5.2%, −4.6%, −4.0%, and −27.1% respectively), indicating a pattern of well-timed exits before declines. This sale occurs when SRPT is −22.6% from its 52-week high, though the stock has risen +21.3% over the past 30 days. The company's recent financial profile shows $467,172,000.00 in quarterly revenue with annual revenue growth of +33.3%, but the company was unprofitable over its most recent full fiscal year, and the P/E of 99.05 reflects elevated growth expectations. The director's reduction of his stake by roughly one-third, combined with a track record of well-timed exits at this ticker specifically, merits attention given the company's valuation profile and profitability status.

CFO Estepan sold 5,985 shares of SRPT at $137.36 (Aug 30); retains 33,946 shares. Stock now -17.6% from 52-week high.

Estepan Ian Michael, Chief Financial Officer, executed a single sale of 5,985 shares for $822,099.60, reducing his holdings by 15.0%. The sale occurred at $137.36, a price that sits between the 52-week low of $67.31 and high of $163.85, and the stock has since declined to $135.10 (-17.6% from the 52-week high). The company reported strong revenue growth of +33.3% year-over-year and achieved a $6.5M net income in the latest quarter, though it was unprofitable over its most recent full fiscal year. With a P/E of 270.20 and $12.9B market cap, the valuation is elevated relative to earnings; the sale represents a routine disposition rather than a dramatic shift in the executive's ownership stake.

Chambers buys 37,038 shares for $4,955,728.14 at SRPT; holds 284,034 shares post-transaction.

Director Michael Andrew Chambers purchased 37,038 shares across 3 separate transactions on 2024-08-16, accumulating $4,955,728.14 in equity and increasing his holdings by 15.0% to 284,034 shares. The purchase prices ranged from $133.07 to $134.66, below the current price of $140.49. Chambers' prior trading activity at Sarepta shows a consistent pattern of weakness over the 90-day window—his 5 prior buys at this ticker generated no positive 90-day outcomes, with returns ranging from -22.9% to -27.7%. The company's P/E ratio of 280.98 reflects elevated valuation relative to the $6.5M net income on $362.9M quarterly revenue, and the stock remains 14.3% below its 52-week high of $163.85. This purchase represents a material commitment but occurs within a historical context where timing at this ticker has not proven favorable on the extended horizon.

EVP/General Counsel Brown sold 38,957 shares (69.5% of holdings) for $6.3M across 7 transactions at prices up to $162.65.

Ryan Edward Brown, EVP and General Counsel of Sarepta Therapeutics, executed 7 separate sales totaling 38,957 shares for $6,296,029.42 on 2024-06-25, reducing his position from 56,086 shares to 17,129 shares. The shares sold at prices ranging from $158.07 to $162.65, with a blended average price of $161.61, near the 52-week high of $163.85. This represents a substantial liquidation of 69.5% of his pre-transaction holdings by an officer with fiduciary responsibilities. While the company achieved strong quarterly revenue of $413.5M and year-over-year growth of 33.3%, it remains unprofitable on a full-year basis with a notably elevated P/E of 878.11. The timing of this multi-tranche sale near the stock's 52-week peak and concurrent with recent strong stock performance (30-day change: +28.0%, 90-day change: +21.4%) merits investor attention regarding executive confidence at current valuations.

SRPT Chief Tech Ops Officer Arif Bilal sold 11,757 shares (40.4% of holdings) for $1,917,891.11 on June 24–25, 2024.

Arif Bilal executed 6 separate sales totaling 11,757 shares for $1,917,891.11 over two trading days (June 24–25, 2024), reducing his holding from 29,120 shares to 17,363 shares. The transactions were executed at prices ranging from $162.31 to $167.13, yielding a blended average of $163.13 per share. This represents a reduction of 40.4% of his pre-transaction holdings. The stock's 52-week high of $163.85 is within the transaction price range, and the company's recent 30-day gain of 28.0% and 90-day gain of 21.4% provide context for the near-peak execution. The company reported strong revenue growth of 33.3% annually and achieved quarterly net income of $36.1M, though it remained unprofitable on a full-year basis per the fundamentals reference. At the current price of $158.06, the executed sales are now above current market value, suggesting execution at favorable pricing relative to today's level.